BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced ...

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced promising ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.00%, which has investors questioning if this is right ...

TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that CEO Seth Lederman, M.D., will present at the Zacks SCR Life Sciences Virtual Investor Forum on Ma ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D ...

Tonix Pharmaceuticals (NASDAQ: TNXP) is working to improve organ transplant success rates with TNX-1500, a third-generation CD40L blocker designed to ...

Heme Malignancies Program: TScan’s two lead TCR-T therapy candidates, TSC-100 and TSC-101, are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), ...

present an important study that applied a high-resolution transposon-based barcoding system to show the clonal contribution of hematopoietic stem and ...

Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents ...